Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126536672 | 12653667 | 2 | F | 20150917 | 20160812 | 20160816 | 20160817 | EXP | CA-ROCHE-1643890 | ROCHE | 46.08 | YR | F | Y | 50.00000 | KG | 20160817 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126536672 | 12653667 | 1 | PS | AVASTIN | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | N3734B01,N3734B02,N3734B03,N3734B04 | 125085 | 400 | MG | SOLUTION FOR INFUSION | Q3W | ||||||
| 126536672 | 12653667 | 2 | SS | AVASTIN | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 12/APR/2016, SHE HAD BEVACIZUMAB INFUSION | N3734B01,N3734B02,N3734B03,N3734B04 | 125085 | 300 | MG | SOLUTION FOR INFUSION | ||||||
| 126536672 | 12653667 | 3 | SS | AVASTIN | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | N3734B01,N3734B02,N3734B03,N3734B04 | 125085 | 250 | MG | SOLUTION FOR INFUSION | |||||||
| 126536672 | 12653667 | 4 | C | TECTA | PANTOPRAZOLE MAGNESIUM | 1 | 0 | ||||||||||||
| 126536672 | 12653667 | 5 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126536672 | 12653667 | 1 | Brain neoplasm malignant |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126536672 | 12653667 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126536672 | 12653667 | Abasia | |
| 126536672 | 12653667 | Asthenia | |
| 126536672 | 12653667 | Bedridden | |
| 126536672 | 12653667 | Body temperature increased | |
| 126536672 | 12653667 | Cognitive disorder | |
| 126536672 | 12653667 | Cough | |
| 126536672 | 12653667 | Eastern Cooperative Oncology Group performance status worsened | |
| 126536672 | 12653667 | Heart rate decreased | |
| 126536672 | 12653667 | Heart rate increased | |
| 126536672 | 12653667 | Infusion related reaction | |
| 126536672 | 12653667 | Mobility decreased | |
| 126536672 | 12653667 | Muscular weakness | |
| 126536672 | 12653667 | Oropharyngeal pain | |
| 126536672 | 12653667 | Oxygen saturation decreased | |
| 126536672 | 12653667 | Pneumonia | |
| 126536672 | 12653667 | Pruritus | |
| 126536672 | 12653667 | Rhinorrhoea | |
| 126536672 | 12653667 | Somnolence | |
| 126536672 | 12653667 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126536672 | 12653667 | 1 | 20150917 | 0 | ||
| 126536672 | 12653667 | 2 | 20160216 | 0 | ||
| 126536672 | 12653667 | 3 | 20160714 | 0 |